Summary
Edwards Lifesciences Corporation's 2012 10-K filing reveals a strong year of growth, driven primarily by its Transcatheter Heart Valves (THV) segment, which saw sales increase by 65.4%. This growth was significantly boosted by the U.S. launch of the Edwards SAPIEN valve in late 2011. The Surgical Heart Valve Therapy segment showed modest growth of 0.4%, while Critical Care sales remained flat. Overall, net sales grew by 13.2% year-over-year, reaching $1.9 billion. The company's financial health appears robust, with a substantial increase in gross profit margin to 74.0% in 2012, up from 70.8% in 2011. This improvement was attributed to a favorable product mix, particularly higher THV sales, and the positive impact of foreign currency exchange rates. Research and development expenses also increased by 18.3%, reflecting continued investment in product innovation, especially within the THV segment, with new valve systems in development. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders.
Financial Highlights
52 data points| Revenue | $1.90B |
| Cost of Revenue | $491.00M |
| Gross Profit | $1.41B |
| R&D Expenses | $291.30M |
| SG&A Expenses | $697.40M |
| Interest Expense | $4.40M |
| Net Income | $291.50M |
| EPS (Basic) | $0.42 |
| EPS (Diluted) | $0.41 |
| Shares Outstanding (Basic) | 689.40M |
| Shares Outstanding (Diluted) | 709.80M |
Key Highlights
- 1Net sales increased by 13.2% to $1.9 billion in 2012, driven by strong performance in Transcatheter Heart Valves (THV).
- 2Transcatheter Heart Valves (THV) segment sales surged by 65.4% to $552.1 million, largely due to the U.S. launch of the Edwards SAPIEN valve.
- 3Gross profit margin improved significantly to 74.0% in 2012 from 70.8% in 2011, benefiting from a favorable product mix and foreign currency impacts.
- 4Research and Development (R&D) spending increased by 18.3% to $291.3 million, highlighting continued investment in innovation, particularly for THV.
- 5The company maintained a strong balance sheet with total assets of $2.22 billion and healthy liquidity.
- 6Edwards Lifesciences continued its share repurchase program, repurchasing $350.3 million of common stock in 2012.
- 7The company operates with a diversified sales base, with 57% of sales generated internationally in 2012.